Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Irritation Study of PF-06700841 Cream
NCT03916250Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of brepocitinib in psoriasis and atopic dermatitis (AD) (6 arms), sponsored by Pfizer. Primary endpoint: Proportion of participants with skin irritation grade >= ++ up to Day 4. Started Mar 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
psoriasisatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03916250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916250.